This roundtable discussion among leading experts in HCV will be recorded immediately following the 2013 EASL meeting in Amsterdam, Netherlands and will explore some of the most recent findings and address the evidence-based clinical application of these data for HCV patients.
Learning Objectives include:
* Evaluate evidence-based clinical data on the safety and efficacy of investigational regimens currently being studiedto treat HCV to assist in current and future clinical decision-making.
* Identify the different mechanisms of action of the various DAA classes and describe the rationale for combinations under investigation for different patient groups.
* Evaluate emerging data on current and new combination therapies in subpopulations of HCV patients, including those with cirrhosis, co-infection, or transplant.
CME credit is available. To register, visit www.hcvwebinar.com, or call 1-855-276-6855.